Alexandra Goll

Ms. Alexandra Goll is General Partner at TVM Capital GmbH which she joined in 1998.
She is also Mitglied des Vorstands at Addex Pharmaceuticals SA. She is on the Board of Directors at Biovertis AG, Arrow Therapeutics Ltd., Cerenis Therapeutics Holding SA, and Albireo AB. Dr. Goll also served on the board at Pharmasset, Inc. Prior to her affiliation with TVM, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel.
She had been involved in clinical development and managing commercialisation strategies of several products.
Dr. Alexandra Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg.